Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation.

Next Previous
X
Search
Trial Profile

A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luminespib (Primary) ; Trastuzumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRY

    • Most Recent Events

    • 26 Nov 2020 Status changed from suspended to completed.
    • 02 Mar 2016 Status changed from recruiting to suspended as per European Clinical Trials Database record.
    • 30 Sep 2014 Interim results in 5 patients presented at the 39th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top